Current approaches to treating of patients with multiple myeloma with renal failure: Questions and proofs

Abstract

Renal failure (RF) is detected in 20-30% of patients at the onset of multiple myeloma (MM), in 50% of patients during its progression. The advent of new, highly effective agents has considerably expanded the possibilities of treatment in MM patients. Unfortunately, patients with RF, especially those with severe RF, were not included in the majority of investigations. The available data are based on the results of treatment in small groups of patients generally without the morphological identification of nephropathies, with varying severity of RF, which explains significant differences in renal response rates. This review analyzes the results of the most important studies and gives recommendations for treatment in accordance with national and international standards.

Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report

“…RI affects up to 50% of patients with MM ( 5 ). Renal failure (RF) is detected in between 20 and 30% patients at the onset of MM, and in 50% of patients during its progression ( 6 ). The prognosis of patients with MM has significantly improved following the introduction of novel concepts of immunomodulation and proteasome inhibition in myeloma therapies ( 7 ).…”